ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Want to see ADCT full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.5Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced solid operational and financial execution (revenue growth ~15%, 13% reduction in adjusted operating expenses, improved GAAP and non-GAAP losses, and a cash runway into 2028) with near-term risks tied to clinical outcomes and ongoing cost reallocation (higher COGS and quarter-over-quarter cash decline). Management highlighted multiple upcoming data catalysts (LOTIS-5, LOTIS-7, IITs) that could materially drive future growth if positive, but outcome uncertainty and no expected 2026 revenue upside temper near-term outlook.Company Guidance
Net Product Revenue Growth
Q1 2026 net product revenues of $20.0M versus $17.4M in Q1 2025, an increase of approximately 15%, driven primarily by quarter-to-quarter customer ordering variability with underlying demand described as broadly stable.
Reduced Operating Expenses (Non-GAAP)
Total adjusted (non-GAAP) operating expenses were $42.9M for Q1 2026, down 13% versus Q1 2025, primarily due to lower R&D spending and active cost management.
Improved Net Loss
GAAP net loss improved to $33.0M ($0.21 per share) in Q1 2026 from $38.6M ($0.36 per share) in Q1 2025 (approximate 14.5% reduction). Non-GAAP adjusted net loss improved to $19.7M from $24.0M (approximate 17.9% reduction).
Cash Balance and Runway
Cash and cash equivalents of $231.0M at March 31, 2026 (down from $261.3M at 12/31/2025), with management stating an expected cash runway at least into 2028.
Upcoming Clinical and Regulatory Catalysts
Multiple near‑term catalysts: expected LOTIS-5 top-line readout before end of June 2026 (Phase III confirmatory trial of ZYNLONTA + rituximab); LOTIS-7 enrollment expected complete in Q2 with full data by year-end 2026; indolent lymphoma IIT data anticipated between end-2026 and mid-2027. Management plans sBLA submission by year-end 2026 if LOTIS-5 is positive.
Commercial Positioning and Long-Term Potential
Management reiterates ZYNLONTA's established role as a single-agent third-line-plus DLBCL therapy and projects potential peak U.S. annual revenues of $600M to $1B assuming compendia listing and regulatory approvals from lifecycle expansion.
ADCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2026 | $4.23 | $4.80 | +13.48% |
Nov 10, 2025 | $4.04 | $4.21 | +4.21% |
Aug 12, 2025 | $2.68 | $2.94 | +9.70% |
May 14, 2025 | $1.32 | $1.81 | +37.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ADC Therapeutics Ltd (ADCT) report earnings?
ADC Therapeutics Ltd (ADCT) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is ADC Therapeutics Ltd (ADCT) earnings time?
ADC Therapeutics Ltd (ADCT) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADCT EPS forecast?
ADCT EPS forecast for the fiscal quarter 2026 (Q2) is -0.21.